Synthekine Secures $100 Million Series C Financing to Advance Pipeline of Engineered Cytokine Therapeutics
January 6, 2023
Copyright 2023 – Synthekine
Press Releases
Fierce Biotech names Synthekine as one of its “Fierce 15” Biotech Companies of 2022
September 12, 2022
Synthekine Doses First Patient in Phase 1 Clinical Trial of IL-2 Partial Agonist, STK-012, for Treatment of Solid Tumors
February 3, 2022
Synthekine Announces Publication of Preclinical Data Demonstrating In Vivo Control of CD19 CAR-T Cells with its Orthogonal IL-2 System
December 23, 2021
Synthekine Establishes Collaboration with Merck to Develop Therapeutic Candidates Using its Proprietary Surrogate Cytokine Agonist Platform
November 1, 2021
Synthekine Advances IL-2 Partial Agonist, STK-012, into Clinical Investigation for Treatment of Solid Tumors
October 28, 2021
Synthekine Strengthens Leadership with Board of Directors Expansion and Scientific Advisory Board Formation
February 4, 2021
Synthekine Launches with $82 Million Series A Financing to Advance Pipeline of Engineered Cytokine Therapeutics Optimized for Cancer and Autoimmune Diseases
September 17, 2020
Synthekine Secures $100 Million Series C Financing to Advance Pipeline of Engineered Cytokine Therapeutics
January 6, 2023
Fierce Biotech names Synthekine as one of its “Fierce 15” Biotech Companies of 2022
September 12, 2022
Synthekine Doses First Patient in Phase 1 Clinical Trial of IL-2 Partial Agonist, STK-012, for Treatment of Solid Tumors
February 3, 2022
Synthekine Announces Publication of Preclinical Data Demonstrating In Vivo Control of CD19 CAR-T Cells with its Orthogonal IL-2 System
December 23, 2021
Synthekine Establishes Collaboration with Merck to Develop Therapeutic Candidates Using its Proprietary Surrogate Cytokine Agonist Platform
November 1, 2021
Synthekine Advances IL-2 Partial Agonist, STK-012, into Clinical Investigation for Treatment of Solid Tumors
October 28, 2021
Synthekine Strengthens Leadership with Board of Directors Expansion and Scientific Advisory Board Formation
February 4, 2021
Synthekine Launches with $82 Million Series A Financing to Advance Pipeline of Engineered Cytokine Therapeutics Optimized for Cancer and Autoimmune Diseases
September 17, 2020